

Supplementary Table S1 Comparative data of the two study groups

| | | Off antifungal prophylaxis (n = 22) | On antifungal prophylaxis (n = 33) | p-Value |
|--------------------------------|-----------|-------------------------------------|------------------------------------|---------------|
| Mean age | | 8.2 (5.1) | 6.3 (4.5) | 0.28 0.083 |
| Age | 1–10 y | 11 (50%) | 25 (75%) | |
| | >10 y | 11 (50%) | 8 (25%) | |
| Gender | Male | 14 (63%) | 22 (67%) | 0.82 |
| | Female | 8 (37%) | 11 (33%) | |
| Final regimen | B | 9 (41%) | 17 (52%) | 0.44 |
| | C | 13 (59%) | 16 (58%) | |
| Central line | Yes | 4 (18%) | 11 (33%) | 0.22 |
| | No | 18 (72%) | 22 (67%) | |
| Type | Chemoport | 2 | 3 | |
| | Femoral | 1 | 0 | |
| Central line Infection | | 1 (33%) | 1 (33%) | 0.77 |
| Associated bacterial infection | | 0 | 4 (12%) | 0.78 |
| Invasive fungal infections | Possible | 9 (56%) | 7 (58%) | 0.008 |
| | Probable | 3 (19%) | 0 | |
| | Proven | 4 (25%) | 5 (42%) | |
| Total | | 16 | 12 | |